Abstract: Cleansing compositions are provided. The mask cleansing composition includes a) A polyvinyl alcohol; b) At least one sugar alcohol; c) At least one surfactant; d) At least one or more hydrophobically-modified polymers; e) At least one silicone oil; and wherein the composition provides the self-bubbling action. The cleansing composition is free of perfluoro compound.

Abstract: The present invention includes a spray drying disposable device for use in a spray drying system. The disposable has a spray drying head and a plasma drying chamber. The head has a spray dry nozzle assembly in fluid communication with the plasma source and the pressurized aerosol gas source. The pressurized gas flows in a vortex pattern that atomizes plasma droplets in the chamber. The head also includes a plenum has uniform air pressure of the drying gas. A baffle plate forms the floor of the plenum having drying gas jets that supply drying gas to the chamber. The atomized plasma droplets evaporate in the presence of the drying gas emitted from the jets to obtain dried plasma particles and humid air. A capture filter captures the dried plasma particles and allows the humid air to pass. The humid air passes through the gas outlet and the exhaust port.

Abstract: Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.

Abstract: Compositions and methods for reducing the growth of and/or preventing the formation of a microbial biofilm are disclosed. The composition comprises an antimicrobial SMR peptide comprising an HIV-1 SMRwt peptide and a cell penetrating peptide (CPP) domain. In some embodiments, the composition further comprises one or more other antimicrobial peptides (AMPs), antibiotics, matrix-inhibiting compounds, matrix-disaggregating compounds, quorum sensing inhibitors, or a combination thereof. In other embodiments, the compositions are used for impregnating or coating an article and/or material surface with the composition to render it less prone to microbial infections.

Abstract: Compositions and methods for reducing the growth of and/or preventing the formation of a microbial biofilm are disclosed. The composition comprises an antimicrobial SMR peptide comprising an HIV-1 SMRwt peptide and a cell penetrating peptide (CPP) domain. In some embodiments, the composition further comprises one or more other antimicrobial peptides (AMPs), antibiotics, matrix-inhibiting compounds, matrix-disaggregating compounds, quorum sensing inhibitors, or a combination thereof. In other embodiments, the compositions are used for impregnating or coating an article and/or material surface with the composition to render it less prone to microbial infections.

Abstract: Disclosed in the present invention are a polypeptide fragment, a derivative of the polypeptide fragment, and applications of the derivative of the polypeptide in the preparation of drugs for preventing and treating fibrosis diseases.

Abstract: The present disclosure relates to a nanoemulsion composition of oxygen gas sustained release and method for preparing the same, and provides a nanoemulsion composition of oxygen gas sustained release and method for preparing the same, including a water phase part containing water, and an oil phase part dispersed in the water phase part and made of nanoparticle containing a perfluorocarbon compound, wherein the oil phase part contains oxygen gas, and the oxygen gas is released in sustained release. According to the present disclosure, there are advantages of preventing hair loss or promoting hair growth by increasing the amount of oxygen gas supplied to the hair bulb and the oxygen release time from the hair bulb.

Abstract: A compound 1-cyclopropyl-6-fluoro-7-(4-(2-hydroxy-3-(naphthalen-2-yloxy)propylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, its synthesis, and its use as an insecticidal agent.

Abstract: An insulin formulation and a method of preparing and using same. The insulin preparation includes insulin, oligosaccharide and sodium chloride at a ratio of 1:A:B (w:w:w respectively) with ranges of A and B are 1000-5000 and 10-50, respectively.

Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Abstract: Methods of making components for a medicinal delivery device are described, in which a base composition comprising a polysulphone is applied to the surface of a component to create a base layer, a primer composition comprising a silane having two or more reactive silane groups separated by an organic linker group is applied to the base layer to create primed surface, and a coating composition comprising an at least partially fluorinated compound is applied to the primed surface. Corresponding coated components and a medicinal delivery device are disclosed.

Abstract: The invention relates to cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection. In particular, the invention provides a cyclosporine liquid formulation for use as an aerosol for inhalation in a method of preventing or treating pulmonary chronic graft rejection in single lung transplanted patients. The formulation is preferably administered once or twice daily. The formulation may be aerosolized with a nebulizer that comprises features for monitoring the time, date and duration of inhalation by the patient, in order to monitor patient adherence. The formulation according to the invention may be combined with standard immunosuppressants and corticosteroids.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: Foaming fluid composition and methods for enhanced oil recovery are provided with enhanced foaming properties. The foaming composition may include a surfactant and Allium sativum oil where Allium sativum oil may be included in an amount ranging from 20 to 75 vol % in respect to the total volume of the surfactant and the Allium sativum oil. Methods of enhancing recovery of oil from an oil containing formation are also provided. Methods may include injecting a foaming composition into the oil containing formation, where the foaming composition may include a surfactant and Allium sativum oil. Methods may also include the foaming composition that includes Allium sativum oil in an amount ranging from 20 to 75 vol % in respect to the total volume of the surfactant and the Allium sativum oil.

Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; psoriasis; ocular discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms) in post-menopausal women; post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

Abstract: Described are methods of administering therapeutic gases comprising high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also described are methods of administering a therapeutic gas comprising nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods of intermittent administration of nitric oxide pulses are also described.

Abstract: The present invention belongs to the area of cosmetics, especially to a delivery system for actives to the skin, such as face masks and facial masks. Particularly, the present invention refers to a delivery system consisting of a basic body comprises nonwoven fibrous materials and an active-substance preparation which is an o/w emulsion or w/o emulsion, and a wetting liquid that comprises one or more actives to activate the delivery system.

Abstract: A pharmaceutically acceptable composition comprising trehalose and a pharmaceutically acceptable excipient and methods of delivering autophagy stimulating trehalose to a patient in need thereof.

Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.

Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

Abstract: A washable pillow comprising of a molded foam core with antimicrobial resistance encased in a washable netting and a sleeve. The pillow may be washed and dried using conventional household methods without significant damage or loss of mechanical properties.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: Products, systems and methods are disclosed for lowering the concentrations of at least one of preservatives and fibrils in a liquid insulin composition. One method comprises replacing at least a portion of at least one of phenol and m-cresol with at least one of cyclodextrins, cyclodextrin polymers, cyclodextrin beads, and an ion exchange resin.

Abstract: The invention relates to an anhydrous cosmetic or dermatological formulation comprising a viscose lipid-containing preparation and propellant gas consisting essentially of one or more substances selected from hydrofluorocarbons, n-butane, isobutane and propane. The formulation permits application to the skin by spraying of an otherwise nonsprayable preparation. The formulation is free from readily volatile solvents, surfactants, and preferably free from silicones.

Abstract: This invention discloses cannabinoids linked with polyethylene glycol chains. The cannabinoid-polyethylene glycol chain molecules have one, two, or more cannabinoids linked with one, two, or more polyethylene glycol chains. Each cannabinoid-polyethylene glycol chain molecule may have one kind of cannabinoid or multiple kinds of cannabinoid. Methods to make these cannabinoid-polyethylene glycol linked chains are disclosed.

Abstract: An intraocular lenses having a plurality of drug-containing microspheres attached to the intraocular lens. The intraocular lenses can be used for patients undergoing cataract surgery and reduces the need for recurrent surgery, follow-up treatment or postoperative eye-drops. Also provides a method for manufacturing such an intraocular lens and the use of an intraocular lens in the treatment of cataract.

Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.

Abstract: The present invention relates to a stable and clear microemulsion comprising: an oil phase comprising an hydrophobic active ingredient; an aqueous phase; and a surfactant system comprising: a non-ionic primary surfactant system; a first non-ionic co-surfactant system, and a second non-ionic co-surfactant system.

Abstract: A multi-chrome cosmetic hair composition is disclosed. The composition includes a base formula suitable for hair and an interference pigment providing a colored background exhibiting interference colors that are observable at different angles of observation. The formula is sufficient to enable a homogenous suspension of the interference pigment. The formula includes a propellant, denatured alcohol, neutralized octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4, a neutralizing agent sufficient to neutralize the octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4 to a range of 80% to 100%, and a plasticizer. The interference pigment includes an opaque-type interference pigment consisting of particles ranging from 5 microns to 60 microns in size to fill in gaps on hair shaft surfaces and create a smooth, chrome-like effect on the hair.

Abstract: Provided herein are novel isotretinoin formulations that provide an enhanced targeted dermal delivery system for the drug isotretinoin with improved thermodynamic activity using no to a small level of ethanol relative to existing isotretinoin gel products, and methods for treatment of ichthyosis and other skin conditions using the same.

Abstract: The invention relates to the non-therapeutic use of a composition comprising at least one 1,4:3,6 dianhydrohexitol for moisturising the skin, as well as to a preparation for topical use comprising at least one 1,4:3,6 dianhydrohexitol as a moisturising agent.

Abstract: This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminoserol, such as squalamine, a naturally occurring aminosterol isolated from Squalus acanthias, or derivatives thereof, to a subject in need.

Abstract: Compositions for treatment or prevention of viral infections, such as influenza A and B, coronaviruses, including but not limited to COVID-19 and any variant thereof, and rhinoviruses, along with related treatment methods. Certain compositions according to preferred embodiments may comprise chlorpheniramine and albuterol administered by inhalation in nebulized form.

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Abstract: A compound having Formula I or its derivative may inhibit metallo-beta-lactamases. An investigation studying the effects of the compounds was provided by the invention of the activities of all subclasses (B1, B2, and B3) metallo-beta-lactamases. The compounds can be used for a pharmaceutical product with the ability to restore an anti-bacterial activity of a beta-lactam antibiotic, thereby treating and preventing a bacterial infection in an animal or human subject.

Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.

Abstract: A method for alleviating, preventing or treating symptoms of a viral infection such as common cold and flu, comprising administering to a subject in need thereof at least one solid form that releases molecular hydrogen upon exposure to the subject's gastric juice.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Provided are a nanoliposome-microbubble conjugate in which a drug for hair loss treatment such as finasteride, minoxidil, dutasteride, etc. is encapsulated in a nanoliposome and a composition for alleviating or treating hair loss containing the same. Since an orally administered agent such as finasteride, currently useful as a drug for hair loss treatment, causes side effects, drug delivery through scalp application is most desirable, but the drug is not delivered to hair follicle cells through scalp application alone. Since a drug for hair loss treatment useful as an external preparation for skin causes various side effects, the concentration thereof that is used needs to be further lowered. The above nanoliposome-microbubble conjugate is capable of increasing the delivery efficiency of a drug for hair loss treatment at a low concentration, and is thus very effective at treating androgenic alopecia.

Abstract: The present invention relates to a composition for killing arthropods and their eggs, such as lice or ticks and nits. More in particular, the invention provides a composition for killing arthropods, said composition comprising at least 65% by weight of a mixture of saturated linear or branched hydrocarbons, wherein said hydrocarbons comprise a mixture of saturated linear or branched C10-C16 hydrocarbons and saturated linear or branched C17-C25 hydrocarbons, wherein the ratio of saturated linear or branched C10-C16 hydrocarbons to saturated linear or branched C17-C25 hydrocarbons by weight is lower than 15:85. The invention further relates to the use of such composition for killing arthropods and to a method for killing arthropods comprising the application of the present composition.

Abstract: The present invention relates to a method for the determination of the film forming amines on surfaces by the detection of a colored complex. The invention also relates to the use of the absorber material for the detection of the film forming amines. The invention also relates to a kit of parts comprising the components capable of the determination of film forming amines.

Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

Abstract: This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.

Abstract: The present disclosure is directed to a composition comprising micronized cromolyn sodium, ?-lactose, and a salt of fatty acid, wherein the ?-lactose has a particle size distribution of D90 of 45-70 ?m, D50 of 10-35 ?m, and D10 of 2-13 ?m. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.

Abstract: Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof.